Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress

By AiT Analyst On Sep 16, 2021

– DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer

– In patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in patients with DKK1-high tumors

– Further results will be presented at the ESMO 2021 Congress from September 16 to 21, 2021

Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.’s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress, being held virtually on September 16-21, 2021. The Company will host a conference call on Friday, September 17, 2021 to discuss preliminary results from the study.

Tessl Raises $125 Million to build AI Native Software Development

Nov 15, 2024

Team-GPT Raises $4.5Million to Discover and Deploy AI Use Cases in Enterprises

Nov 15, 2024

Ironclad Launches Jurist: an AI-Powered Assistant That Shows its Work

Nov 15, 2024

Prev Next 1 of 40,548

“Initial data from the DisTinGuish study is extremely promising as it shows DKN-01 in combination with tislelizumab and chemotherapy to have high response rates in first-line patients suffering from gastric and gastroesophageal junction cancer,” said Cynthia Sirard, MD, Chief Medical Officer of Leap. “Patients whose tumors have high levels of DKK1 expression, which is known to correlate with aggressive disease and poor prognosis, showed the highest response rates, suggesting how important the biomarker may be in predicting response to therapy. Additional data will be presented at ESMO and in our conference call to demonstrate the potential DKN-01 has as part of first-line therapy in this difficult-to-treat indication.”